Clario, a US-based provider of endpoint data solutions to the clinical trial industry, announced on Wednesday a multi-year agreement with Amazon Web Services (AWS) to advance its generative AI platform.
By leveraging AWS's AI and machine learning technologies, Clario said that it intends to enable healthcare and life sciences organisations to process complex documents and trial data with enhanced speed and accuracy, reducing clinical trial startup times.
According to Clario, its proprietary generative AI platform orchestrates multiple large language models and deep learning models using AWS infrastructure to achieve best in class results. This scalable system enables the rapid processing of clinical documents and multi-modal data, transforming vast volumes of unstructured information into actionable insights, empowering life sciences companies to accelerate innovation. By adopting an iterative approach to model development and optimising each phase of analysis, Clario said that it is delivering a scalable solution tailored to the unique challenges of clinical trials.
"We're excited to work with Clario to support the advancement of clinical trial data management using generative AI to analyse endpoint data across imaging, cardiac safety, eCOA and respiratory assessments," commented Allyson Fryhoff, AWS managing director of Healthcare & Life Sciences. "Their work underscores the huge opportunity that advanced technologies bring to drug development by transforming unstructured data into insights that help sponsors get effective therapies to patients faster than ever before."
Cinclus Pharma signs EUR220m European commercialisation deal with Zentiva for acid reflux therapy
Sanofi to acquire Vigil Neuroscience for USD470m to expand Alzheimer's pipeline
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
Revalesio reports further analysis from Phase 2 RNS60 trial for acute ischemic stroke treatment
AnnJi reports positive Phase 1/2a results in Spinal and Bulbar Muscular Atrophy trial
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
MSD expands clinical development of Orion's opevesostat to include women's cancers
Promontory Therapeutics reports successful FDA meeting after Phase 2 study of PT-112
Trevi Therapeutics reports additional results from Phase 2a RIVER trial of Haduvio
Accropeutics reports positive data from Phase 2 psoriasis treatment trial
NextCell Pharma partners with Fujifilm Irvine Scientific to deliver integrated MSC solutions
Lifecare files for first human trial of glucose monitoring implant, targeting CE-mark
EXACT Therapeutics reports strong Phase 1 results for ACTIVATE trial in colorectal liver metastases